BioHarvest Sciences (BHST) Projected to Post Quarterly Earnings on Thursday

BioHarvest Sciences (NASDAQ:BHST) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.16) per share and revenue of $9.31 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). BioHarvest Sciences had a negative return on equity of 58.30% and a negative net margin of 31.21%. The firm had revenue of $8.84 million during the quarter, compared to analyst estimates of $9.45 million. On average, analysts expect BioHarvest Sciences to post ($0.58) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.

BioHarvest Sciences Stock Performance

Shares of BHST opened at $1.75 on Tuesday. The stock has a 50 day moving average price of $1.66 and a 200 day moving average price of $3.15. BioHarvest Sciences has a one year low of $1.37 and a one year high of $8.30. The stock has a market capitalization of $34.34 million, a price-to-earnings ratio of -3.37 and a beta of 0.93.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BHST shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Monday, September 14th. Roth Capital reduced their target price on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Finally, Maxim Group reduced their target price on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.50.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency.

The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.